Farmavita.Net is network for pharmaceutical licensing and regulatory affairs. http://www.farmavita.net Sat, 31 Jul 2010 13:16:34 +0100 FeedCreator 1.7.2 http://www.farmavita.net/images/M_images/rss20.gif http://www.farmavita.net Farmavita.Net is network for pharmaceutical licensing and regulatory affairs. http://www.farmavita.net/content/view/1524/84/ Sydney, Australia, July 30, 2010: GenericsWeb, a leader in established pharmaceutical patent searching and analysis, recently published an article based on its proprietary patent intelligence for Aricept® (Donepezil), the world's best selling anti-Alzheimer's drug developed by Eisai and co-marketed with Pfizer. The article analyses the patent landscape surrounding Donepezil, highlighting the need for comprehensive patent information in the development of launch strategies for generic products to minimise the risk of litigation. Key findings of the article include: # The patentee Eisai has so far been successful in defending the Donepezil molecule patent from attacks by generic manufacturers in the US; but whilst litigation is ongoing, Eisai has taken measures to prevent early 'at risk' launch following expiry of the 30 month stay. # Eisai has embarked on a life-cycle management strategy resulting in key patents being identified for polymorphic forms and formulations protecting certain dosage forms. However, these patents will unlikely delay generic launch beyond the 'molecule' patent, as they appear to be relatively easily circumvented by forward-thinking generic competitors. # Generic equivalents of all currently authorised dosage forms Aricept® are likely to become available in the US during November 2010, and in most European countries during February 2012 from numerous suppliers, resulting in substantial pricing pressure. You can read the full article here: http://www.genericsweb.com/druginfocus/Donepezil ABOUT GENERICSWEB – THE SEARCH IS OVERGenericsWeb, the leader in pharmaceutical patent searching and analysis holds an impeccable track record in providing quality patent information, allowing numerous pharmaceutical companies to successfully navigate intellectual property hazards. GenericsWeb is headquartered in Sydney, Australia, with offices in North America and Europe. Our technical staff is highly skilled and experienced and has extensive experience in pharmaceutical sciences and patent searching. For more information, visit the company's web site at www.genericsweb.com Business News - Press Release Fri, 30 Jul 2010 10:08:04 +0100 http://www.farmavita.net/content/view/1522/84/ Calcitriol Soft gel Dossier Interested in purchasing a ECTD dossier for Calitriol Softgels 0.25 0.5mcg. Pharma In-Licensing - License-in Demand Wed, 21 Jul 2010 11:16:35 +0100 http://www.farmavita.net/content/view/1503/84/ Hello We are looking to license drugs in the last stages of clinical development in the area of neurology, brain diseases, eye diseases and the like for Russian/CIS market. Thanks Natalia Volodina, Ph.D. volodina@geropharm.ru (mailto:volodina@geropharm.ru) Manager of preclinical development Geropharm St Petersburg, Russia Pharma In-Licensing - License-in Demand Thu, 15 Jul 2010 14:50:15 +0100 http://www.farmavita.net/content/view/1479/84/ Future treatment will be based on individual tumor gene expression signatures The majority of patients present with early-stage melanoma, when surgery is often curative. Patients with metastatic disease are poorly served by current drugs, with very few approved treatment options and no widely accepted standard of care. A significant unmet need therefore remains for more effective agents, which has made melanoma a popular R D target. Business Reports - Forecast Wed, 23 Jun 2010 15:41:43 +0100 http://www.farmavita.net/content/view/1474/84/ I am looking for a Mezlocillin injection formulation for Asia. CPP from the company havign the MA is needed. Supply of the formulated product is also needed. Best regards, Michel Bulliard Pharma In-Licensing - Generic Medicine Demand Thu, 17 Jun 2010 12:49:44 +0100 http://www.farmavita.net/content/view/1463/84/ Analyzing Market Trends and Regulatory Impacts With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible. Business Reports - Market Report Thu, 10 Jun 2010 12:52:47 +0100 http://www.farmavita.net/content/view/1457/84/ Demand: Innovative Arthritis Medicine Farmavita.Net member is developing innovative concept for glogal branding and distribution of remedies and devices for therapy of arthritis. Company is looking to joint-venture, collaborative development or in-licensing of non-prescrition products, on exclusive basis. For more details please contact Farmavita.Net. Pharma In-Licensing - Innovative Medicine Demand Wed, 09 Jun 2010 01:11:28 +0100 http://www.farmavita.net/content/view/1454/84/ Open source systems lure drug developers The gradual spread of software automation in drug development may be getting a boost from open source systems. Most e-clinical systems today--from data capture and storage to trial management and operations--are proprietary, despite the excellent work that solutions providers have done to make their products compatible with existing standards-based and de facto standard industry systems. Business News - Open Innovation Fri, 04 Jun 2010 12:51:44 +0100 http://www.farmavita.net/content/view/1453/84/ GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria GSK becomes first company to freely share chemical structures on 13,500 molecules from its compound library Alliances formed with leading scientific research communities from private industry and public-domain data provider May 19, 2010/Burlingame, CA/ GlaxoSmithKline (GSK) had teamed up with leading public-domain data providers European Bioinformatics Institute (EMBL-EBI), the U.S. National Library of Medicine (NLM) and the US-based informatics service provider Collaborative Drug Discovery (CDD) to make freely available key scientific information on more than 13,500 compounds that could ultimately lead to new treatments for malaria. Business News - Open Innovation Fri, 04 Jun 2010 12:43:46 +0100 http://www.farmavita.net/content/view/1437/84/ Dendreon: landmark cancer vaccine approval but high costs may hinder uptake Having been approved by the FDA in castration-resistant prostate cancer, Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market. This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used. Business News - Press Release Fri, 07 May 2010 13:10:57 +0100 http://www.farmavita.net/content/view/1422/84/ Second annual Pharmaceutical Risk-Sharing Value-based Pricing and Reimbursement Models Bratislava, 15-16 th April 2010 Not being a specialist in the area of Risk-Sharing Value-based Pricing this event was an excellent introduction for me. Meeting P R experts from some of the most important pharma companies in the world as well as hearing their detailed presentations was a really good experience. The event was splendidly organised by Next Level Pharma in Trend Hotel,Bratislava, SK, near the city centre, which was an excellent location. The overall impession was ruined only by a bad weather which did not allow a proper sightseeing of the city and disturbed air traffic which made problems to the return flight of most participants. Business News - Press Release Mon, 26 Apr 2010 14:48:05 +0100 http://www.farmavita.net/content/view/1410/84/ Big Pharma Mega-Mergers 1995-2014 Mega-mergers (defined here as M A events with deal sizes >$5bn) have been a long-term strategic feature of the pharmaceutical industry and have played a key role in shaping the structure and composition of today's leading companies. Is it possible to quantify exactly how much of Big Pharma's sales growth has been driven by M A versus how much has been self-produced through organic growth? Business Reports - Forecast Tue, 06 Apr 2010 10:59:29 +0100 http://www.farmavita.net/content/view/1395/84/ Big pharma struggles to benefit from increased CVD drug usage London - Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research* by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107bn in 2018. Patent expiries and generic competition will have a major impact and Datamonitor expects AstraZeneca and Novo Nordisk to emerge as the only major CVD pharma companies to generate positive sales growth over the period. Business News - Press Release Mon, 15 Mar 2010 12:42:58 +0100 http://www.farmavita.net/content/view/1389/120/ Lacerta BioCapital Lacerta BioCapital, a member of Farmavita.Net, invests in sound, stable companies in promising Life Science segments with attractive futures (e.g., sustained positive cash flow; value increase potential of at least 20% p.a.; growth potential either organically or through acquisition; etc.). Our target companies have a sound customer base with a well balanced product portfolio. We aim to have a total investment budget of approximately €300 million (including credit capital), to be invested in around 10-15 Life Science companies. Please contact us for introduction to Lacerta BioCapital. Business News - Business for Sale Thu, 25 Feb 2010 12:06:56 +0100 http://www.farmavita.net/content/view/1368/57/ Our company offers probiotics in sachets or capsules in any concentration and containing any strains. We are very competitive in terms of prices and we are very flexible in terms of minimum batch. Pharma Out-Licensing - OTC / Nutraceutical - Offer Fri, 12 Feb 2010 16:48:31 +0100